- Home
- DYAI vs TPST Comparison
DYAI vs TPST Comparison
Compare DYAI & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYAI
- TPST
- Stock Information
- Founded
- DYAI 1979
- TPST 2011
- Country
- DYAI United States
- TPST United States
- Employees
- DYAI N/A
- TPST N/A
- Industry
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- DYAI Health Care
- TPST Health Care
- Exchange
- DYAI Nasdaq
- TPST Nasdaq
- Market Cap
- DYAI 29.6M
- TPST 33.0M
- IPO Year
- DYAI 2004
- TPST N/A
- Fundamental
- Price
- DYAI $0.93
- TPST $7.44
- Analyst Decision
- DYAI Strong Buy
- TPST Hold
- Analyst Count
- DYAI 1
- TPST 3
- Target Price
- DYAI $6.00
- TPST $30.00
- AVG Volume (30 Days)
- DYAI 60.7K
- TPST 234.4K
- Earning Date
- DYAI 08-12-2025
- TPST 08-07-2025
- Dividend Yield
- DYAI N/A
- TPST N/A
- EPS Growth
- DYAI N/A
- TPST N/A
- EPS
- DYAI N/A
- TPST N/A
- Revenue
- DYAI $3,554,344.00
- TPST N/A
- Revenue This Year
- DYAI $22.56
- TPST N/A
- Revenue Next Year
- DYAI $30.95
- TPST N/A
- P/E Ratio
- DYAI N/A
- TPST N/A
- Revenue Growth
- DYAI 57.59
- TPST N/A
- 52 Week Low
- DYAI $0.91
- TPST $5.35
- 52 Week High
- DYAI $2.20
- TPST $30.03
- Technical
- Relative Strength Index (RSI)
- DYAI 41.84
- TPST 56.13
- Support Level
- DYAI $0.91
- TPST $7.06
- Resistance Level
- DYAI $1.06
- TPST $7.18
- Average True Range (ATR)
- DYAI 0.06
- TPST 0.28
- MACD
- DYAI 0.00
- TPST 0.03
- Stochastic Oscillator
- DYAI 15.33
- TPST 93.18
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.